Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
EUCRW was delisted on the 26th of April, 2023.
22 hedge funds and large institutions have $731K invested in Eucrates Biomedical Acquisition Corp. Warrant in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.
12% less funds holding
Funds holding: 25 → 22 (-3)
32% less capital invested
Capital invested by funds: $1.08M → $731K (-$352K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$5.53K |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.38K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.25K |
| 4 |
CS
Clear Street
New York
|
+$182 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$7.08K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.98K |
| 3 |
Goldman Sachs
New York
|
-$1.39K |
| 4 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$891 |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$851 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PC
26
Periscope Capital
Toronto,
Ontario, Canada
| – | -$851 | -15,300 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$75 | -1,255 | Closed |
|
EUCRW Hedge Fund Activity: Q1 2023 in Review
22 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q1 2023, worth a combined $731K — down 32% from $1.08M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EUCRW and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Cowen and Company, adding an estimated $5.53K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $7.08K sold.
- 22 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q1 2023, down from 25 in Q4 2022.
- Funds reported $731K of Eucrates Biomedical Acquisition Corp. Warrant stock for Q1 2023, down 32% quarter-over-quarter.
- 4 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q1 2023 and 6 closed out, a net change of -2 holders.
- The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q1 2023 was Cowen and Company, an estimated $5.53K added.
- The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q1 2023 was Granite Point Capital Management, an estimated $7.08K sold.
Based on aggregated 13F filings for Q1 2023.